专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06825362B2 Process for lactonization to produce highly pure simvastatin 失效
标题翻译：内酯化制备高纯度辛伐他汀的方法
公开(公告)号：US06825362B2
公开(公告)日：2004-11-30
申请号：US10602463
申请日：2003-06-23
申请人： Ramesh Dandala , Sonny Sebastian , Dandala Subramanyam , Meenakshisunderam Sivakumaran
发明人： Ramesh Dandala , Sonny Sebastian , Dandala Subramanyam , Meenakshisunderam Sivakumaran
IPC分类号： C07D30910
CPC分类号： C07D309/30
摘要： There is disclosed, a process for lactonization to produce highly pure simvastatin of Formula I which comprises lactonization of a compound of Formula II where Z is H or NH4 in a mixture of acetonitrile and glacial acetic acid under anhydrous conditions at a temperature of 65-70° C.
摘要翻译：公开了一种制备式I的高纯度辛伐他汀的方法，其包括在无水条件下在65-70℃的温度下在乙腈和冰醋酸的混合物中Z为H或NH 4的式II化合物的内酯化。

2. 发明授权

US06797831B2 Process for lactonization to produce simvastatin 失效
标题翻译：内酯化生产辛伐他汀的方法
公开(公告)号：US06797831B2
公开(公告)日：2004-09-28
申请号：US10440537
申请日：2003-05-19
申请人： Ramesh Dandala , Sonny Sebastian , Sanapureddy Jagan Mohan Reddy , Meenakshisunderam Sivakumaran
发明人： Ramesh Dandala , Sonny Sebastian , Sanapureddy Jagan Mohan Reddy , Meenakshisunderam Sivakumaran
IPC分类号： C07D30930
CPC分类号： C07D309/30
摘要： There is disclosed a process for the manufacture of simvastatin of Formula I which comprises heating a compound, namely acid or ammonium salt of compound of Formula II, where Z is H or NH4 in an organic solvent at a temperature of 130-140° C.
摘要翻译：公开了制备式I的辛伐他汀的方法，其包括在130-140℃的温度下，在有机溶剂中加热化合物即式II化合物的酸或铵盐，其中Z是H或NH 4。

3. 发明申请

US20090246284A1 O-desmethylvenlafaxine Cocrystals 审中-公开
标题翻译： O-去甲基蓝法素Cystystals
公开(公告)号：US20090246284A1
公开(公告)日：2009-10-01
申请号：US12415052
申请日：2009-03-31
申请人： Sonny Sebastian , Krishna Challa , Nitin Sharadchandra Pradhan , Jon Valgeirsson
发明人： Sonny Sebastian , Krishna Challa , Nitin Sharadchandra Pradhan , Jon Valgeirsson
IPC分类号： A61K9/14 , A61K31/191 , A61P25/24
CPC分类号： A61K31/191 , C07B2200/13 , C07C55/10 , C07C215/64 , C07C2601/14
摘要： Disclosed herein are co-crystals comprising O-desmethylvenlafaxine and succinic acid, process for the preparation, pharmaceutical compositions, and method of treating thereof.
摘要翻译：本文公开了包含O-去甲基文拉法辛和琥珀酸的共晶体，其制备方法，药物组合物及其处理方法。

4. 发明申请

US20110178326A1 UNSATURATED CINACALCET SALTS AND PROCESSES FOR PREPARING CINACALCET HYDROCHLORIDE 审中-公开
标题翻译：不饱和的CINACALCET SALTS和制备CINACALCET HYDROCHLORIDE的方法
公开(公告)号：US20110178326A1
公开(公告)日：2011-07-21
申请号：US13057796
申请日：2009-08-06
申请人： Sonny Sebastian , Seetha Rama Sarma , Katikireddy Ramamurthy , Nitin Sharadchandra Pradhan
发明人： Sonny Sebastian , Seetha Rama Sarma , Katikireddy Ramamurthy , Nitin Sharadchandra Pradhan
IPC分类号： C07C271/14 , C07C209/70 , C07C209/68 , C07C211/30 , C07C209/86
CPC分类号： C07C209/70 , C07C209/84 , C07C211/30 , C07C269/04 , C07C271/14
摘要： Disclosed herein are convenient, industrially advantageous and environmentally friendly processes for the preparation of cinacalcet hydrochloride. Disclosed also herein are novel hydrochloride, oxalate and di-p-toluoyl-L-(+)-tartrate salts of (R)-α-methyl-N-[3-[3-(trifluoromethyl)phenyl]propylene]-1-naphthalenemethaneamine (unsaturated cinacalcet), solid state forms of the salts, and a process for their preparation thereof.
摘要翻译：本文公开了用于制备盐酸西那卡塞的方便，工业上有利且环境友好的方法。本文还公开了（R）-α-甲基-N- [3- [3-（三氟甲基）苯基]丙烯] -1-甲基吗啉的新型盐酸盐，草酸盐和二对甲苯酰-L-（+） - 酒石酸盐萘甲烷（不饱和西那卡塞），盐的固体形式及其制备方法。

5. 发明申请

US20110046231A1 SOLID FORMS OF (±)-O-DESMETHYLVENLAFAXINE SALTS 审中-公开
标题翻译：（±） - - 去甲苯磺草酮盐的固体形式
公开(公告)号：US20110046231A1
公开(公告)日：2011-02-24
申请号：US12739163
申请日：2008-10-21
申请人： Sonny Sebastian , Raman Buddhavarapu Pattabhi , Krishna Challa , Nitin Sharadchandra Pradhan , Jon Valgeirsson
发明人： Sonny Sebastian , Raman Buddhavarapu Pattabhi , Krishna Challa , Nitin Sharadchandra Pradhan , Jon Valgeirsson
IPC分类号： A61K31/137 , C07C217/74
CPC分类号： C07C215/64 , C07B2200/13 , C07C55/07 , C07C59/08 , C07C63/08 , C07C215/66 , C07C2601/14
摘要： The present invention relates to solid forms of (±)-O-desmethylvenlafaxine salts, processes for preparation, pharmaceutical compositions, and method of treating thereof. More particularly, the present invention provides solid forms of acid addition salts of (±)-O-desmethylvenlafaxine wherein the acid counter ion is provided by an acid selected from the group consisting of oxalic acid, benzoic acid and lactic acid.
摘要翻译：本发明涉及（±）-O-去甲基文拉法辛盐的固体形式，制备方法，药物组合物及其处理方法。更具体地说，本发明提供（±）-O-去甲基文拉法辛的酸加成盐的固体形式，其中酸抗衡离子由选自草酸，苯甲酸和乳酸的酸提供。

6. 发明申请

US20110318417A1 HIGHLY PURE CINACALCET OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF 审中-公开
标题翻译：高纯度CINACALCET或其药学上可接受的盐
公开(公告)号：US20110318417A1
公开(公告)日：2011-12-29
申请号：US13133276
申请日：2009-12-08
申请人： Sonny Sebastian , Seetha Rama Sarma Peri , Katikireddy Ramamurthy , Nitin Sharadchandra Pradhan
发明人： Sonny Sebastian , Seetha Rama Sarma Peri , Katikireddy Ramamurthy , Nitin Sharadchandra Pradhan
IPC分类号： A61K9/14 , A61K31/137 , A61P5/18 , C07C211/30
CPC分类号： C07C211/30 , C07C291/04 , C07C2602/10
摘要： Provided herein are impurities of cinacalcet, (R)-α-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-(5,6,7,8-tetrahydronaphthalene)methaneamine (tetrahydro cinacalcet impurity), (R)-α-Methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethaneamine-N-oxide (cinacalcet N-oxide impurity) and (R)-α-methyl-N-[3-[3-(trifluoromethyl)phenyl]methyl]-1-naphthalenemethaneamine (benzylamine impurity); and processes for preparation and isolation thereof. Provided further herein is a highly pure cinacalcet or a pharmaceutically acceptable salt thereof substantially free of impurities, processes for the preparation thereof, and pharmaceutical compositions comprising highly pure cinacalcet or a pharmaceutically acceptable salt thereof substantially free of impurities.
摘要翻译：本文提供西那卡塞的杂质，（R）-α-甲基-N- [3- [3-（三氟甲基）苯基]丙基] -1-（5,6,7,8-四氢萘）甲胺（四氢西那卡塞杂质），（R）-α-甲基-N- [3- [3-（三氟甲基）苯基]丙基] -1-萘甲烷胺-N-氧化物（西那卡塞N-氧化物杂质）和（R）-α-甲基-N- [3- [3-（三氟甲基）苯基]甲基] -1-萘甲烷胺（苄胺杂质）; 以及其制备和分离方法。本文进一步提供了基本上不含杂质的高纯度西那卡塞或其药学上可接受的盐，其制备方法和包含高纯度西那卡塞或其药学上可接受的盐基本上不含杂质的药物组合物。

7. 发明申请

US20100197732A1 Repaglinide Substantially Free of Dimer Impurity 审中-公开
标题翻译：瑞格列奈基本上不含二聚体杂质
公开(公告)号：US20100197732A1
公开(公告)日：2010-08-05
申请号：US12663106
申请日：2008-06-05
申请人： Sonny Sebastian , Sasidhar Venkata Balla , Ramamurthy Katikareddy , Nitin Sharadchandra Pradhan , Jon Valgeirsson
发明人： Sonny Sebastian , Sasidhar Venkata Balla , Ramamurthy Katikareddy , Nitin Sharadchandra Pradhan , Jon Valgeirsson
IPC分类号： A61K31/4545 , C07D211/26 , C07D211/32 , A61K31/4453 , A61P3/10
CPC分类号： C07D295/135
摘要： The present invention provides highly pure repaglinide substantially free of dimer impurity, and process for the preparation thereof. The present invention also relates to 2-ethoxy-N-[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzamide, an impurity of repaglinide, and a process for preparing and isolating thereof. The present invention further relates to pharmaceutical compositions comprising solid particles of pure repaglinide substantially free of dimer impurity or pharmaceutically acceptable salts thereof, wherein 90 volume-percent of the particles (D90) have a size of less than about 400 microns. The present invention also provides an optical resolution method of racemic 3-methyl-1-(2-piperidino-phenyl)-1-butylamine and use thereof for the preparation of repaglinide.
摘要翻译：本发明提供了基本上不含二聚体杂质的高纯度瑞格列奈及其制备方法。本发明还涉及2-乙氧基-N - [（1S）-3-甲基-1- [2-（1-哌啶基）苯基]丁基] -4- [2 - [[（1S）-3-甲基 -1- [2-（1-哌啶基）苯基]丁基]氨基] -2-氧代乙基]苯甲酰胺，瑞格列奈的杂质及其制备和分离方法。本发明还涉及包含基本上不含二聚体杂质的纯瑞格列奈的固体颗粒或其药学上可接受的盐的药物组合物，其中90体积％的颗粒（D90）具有小于约400微米的尺寸。本发明还提供外消旋3-甲基-1-（2-哌啶子基 - 苯基）-1-丁胺的光学拆分方法及其在制备瑞格列奈中的应用。

8. 发明授权

US06603003B2 Method for the preparation of piperazine and its derivatives 失效
标题翻译：哌嗪及其衍生物的制备方法
公开(公告)号：US06603003B2
公开(公告)日：2003-08-05
申请号：US10037309
申请日：2001-10-25
申请人： Sonny Sebastian , Hetal Virendra Patel , Rajamannar Thennati
发明人： Sonny Sebastian , Hetal Virendra Patel , Rajamannar Thennati
IPC分类号： C07D24104
CPC分类号： C07D295/023 , C07D241/04 , C07D471/14
摘要： A novel method for the synthesis of piperazine and its derivatives of formula 1, wherein R is selected from hydrogen, or a lower alkyl group having 1 to 6 carbon atoms or a phenylalkyl group the alkyl of which has 1 to 4 carbon atoms; R1 is selected from hydrogen, a methyl group, a phenyl group optionally substituted with an alkyl group having 1 to 6 carbon atoms, or a phenylalkyl group the alkyl of which has 1 to 4 carbon atoms; and R2 is selected from hydrogen, or a methyl group, or a fluoromethyl group; comprising the steps: a. reacting an ester of formula 11 with substituted or unsubstituted ethylenediamine of formula 7 to give 3,4-dehydropiperazine-2-one and its derivatives of formula 12, wherein R, R1, R2 are as defined above and R6 is a C1 to C4 linear or branched alkyl group; and b. reacting the 3,4-dehydro-piperazine-2-one and its derivatives of formula 12 with a reducing agent to yield the piperazine and its derivatives of formula 1.
摘要翻译：合成哌嗪及其衍生物的新颖方法，其中R选自氢或具有1至6个碳原子的低级烷基或苯基烷基，其烷基具有1至4个碳原子; R 1为选自氢，甲基，任选被具有1至6个碳原子的烷基取代的苯基，或其烷基具有1至4个碳原子的苯基烷基; 和R 2选自氢或甲基或氟甲基;所述方法包括以下步骤：a。使式11的酯与取代或未取代的式7的乙二胺反应，得到3,4-脱水哌嗪-2-酮及其式12的衍生物，其中R，R 1，R 2如上所定义，R 6是C 1至C 4直链或支链烷基; 安布使3,4-脱氢 - 哌嗪-2-酮及其式12的衍生物与还原剂反应，得到哌嗪及其式1的衍生物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式